CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH
TSPYL5 Suppresses p53 Levels and Function by Physical Interaction with USP7
Here, researchers report that high TSPYL5 (TSPY-like 5) expression is an independent marker of poor outcome in breast cancer. [Nat Cell Biol]
Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer
Here, researchers identify the PIP3-G(beta)(gamma)-dependent Rac-GEF P-Rex1 as an essential mediator of Rac1 activation, motility, cell growth, and tumorigenesis driven by ErbB receptors in breast cancer cells. [Mol Cell]
Linking Transgene Expression of Engineered Mesenchymal Stem Cells and Angiopoietin-1-Induced Differentiation to Target Cancer Angiogenesis
When injected into the peripheral circulation of mice with either, orthotopic pancreatic or spontaneous breast cancer, the engineered mesenchymal stem cells (MSCs) were actively recruited to growing tumor vasculature and induced the selective expression of either reporter red florescent protein or suicide genes [herpes simplex virus-thymidine kinase (TK) gene] when the adoptively transferred MSC developed endothelial-like characteristics. [Ann Surg]
Recovery of Anoikis in Src-Transformed Cells and Human Breast Carcinoma Cells by Restoration of the SIRP(Alpha)1/ SHP-2 Signaling System
In this study, researchers investigated the role of the protein tyrosine phosphatase SHP-2 in signal regulatory protein alpha1 activity. [Cancer Res]
A Mammaglobin-A Targeting Agent for Non-Invasive Detection of Breast Cancer Metastasis in Lymph Nodes
Here, researchers describe an imaging platform for non-invasive assessment of axillary lymph node status, eliminating the need for surgical examination of patients to rule out nodal involvement. [Cancer Res]
Na(v)1.5 Enhances Breast Cancer Cell Invasiveness by Increasing NHE1-Dependent H+ Efflux in Caveolae
Here, researchers showed that the Na+/H+ exchanger type 1 (NHE1) was an important regulator of H+ efflux in breast cancer cells MDA-MB-231 and that its activity was increased by Na(v)1.5. [Oncogene]
Hedgehog Signaling (Hh) Induced by Breast Cancer Cells Promotes Osteoclastogenesis and Osteolysis
In the present study researchers show that the Hh ligands secreted by breast cancer cells promote osteoclast differentiation and potentiate the activity of mature osteoclasts. [J Biol Chem]
A Long AAAG Repeat Allele in the 5′ UTR of the ERR-Gamma Gene Is Correlated with Breast Cancer Predisposition and Drives Promoter Activity in MCF-7 Breast Cancer Cells
The study indicates that the AAAG tetranucleotide repeat polymorphism in estrogen-related receptor-gamma gene 5′ UTR region may be a new biomarker for genetic susceptibility to breast cancer. [Breast Cancer Res Treat]
CLINICAL RESEARCH
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy
This report describes a single-arm phase II study (TDM4258g) that assessed efficacy and safety of intravenous T-DM1 (3.6 mg/kg every 3 weeks) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had tumor progression after prior treatment with HER2-directed therapy and who had received prior chemotherapy. [J Clin Oncol]
Quality of Life After Breast Cancer Diagnosis and Survival
The purpose of this study was to examine the association of quality of life after diagnosis of breast cancer with mortality and recurrence. [J Clin Oncol]
|
|
INDUSTRY NEWS
Quantum Immunologics Announces Appointment of Dr. George Peoples to Scientific Advisory Board
Quantum Immunologics, Inc. (QI), a Tampa, FL-based company currently engaged in an FDA-authorized clinical study of its autologous dendritic cell immunotherapy for Stage IV breast cancer patients, is pleased to announce the appointment of Dr. George E. Peoples, M.D., of Brooke Army Medical Center, San Antonio, TX to QI’s Scientific Advisory Board. [Quantum Immunologics, Inc. Press Release]
Roche’s Avastin Faces FDA Withdrawal in Breast Cancer
Roche Holding AG’s top-selling drug Avastin should no longer be used to treat breast cancer after recent studies failed to show a benefit, U.S. regulators said. [Bloomberg]
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
